LXF-289 Cells

The LxF-289 cell line is a human lung adenocarcinoma cell line established from a 63-year-old male patient. This cell line has a doubling time of approximately 50 hours, making it suitable for studies that require consistent cell proliferation. LxF-289 is particularly valuable in research focused on lung cancer, especially non-small cell lung cancer (NSCLC), as it provides a robust in vitro model for studying the molecular mechanisms underlying cancer progression, treatment resistance, and the effects of therapeutic interventions. Studies on LxF-289 have demonstrated that this cell line exhibits characteristics that make it responsive to specific genetic and therapeutic manipulations. For instance, research has shown that LxF-289, along with other lung cancer cell lines, can undergo significant cell death when treated with an adenovirus expressing antisense heat shock protein 70 (Hsp70). This cell death is p53-independent and does not require DNA cleavage, suggesting that Hsp70 plays a crucial role in the survival of lung cancer cells. Notably, this response is selective to cancer cells, as normal lung fibroblasts and bronchial epithelial cells do not show similar levels of cytotoxicity when Hsp70 is downregulated, highlighting the potential of targeting Hsp70 in lung cancer therapy. Moreover, LxF-289 has been used to study the effects of irradiation on drug resistance-related proteins. The cell line exhibited overexpression of glutathione S-transferase (GSTπ) at both mRNA and protein levels following irradiation. This overexpression is associated with the development of multidrug resistance, which is a significant challenge in the clinical management of lung cancer. These findings underscore the utility of LxF-289 in exploring the mechanisms of resistance and testing novel strategies to overcome it.